A trial of D-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 27, Issue 2, 2015, Pages 133-138

  Urbano, Maria ^a   Okwara, Leonore ^a   Manser, Paul ^b   Hartmann, Kathrin ^a   Deutsch, Stephen I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CLOMIPRAMINE; CLONIDINE; CYCLOSERINE; DEXAMPHETAMINE; METHYLPHENIDATE; OXCARBAZEPINE; RISPERIDONE; ANTIMETABOLITE;

ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; ANTISOCIAL PERSONALITY DISORDER; ARTICLE; AUTISM; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FATIGUE; FEMALE; FOLLOW UP; HAND TREMOR; HUMAN; INCREASED APPETITE; IRRITABILITY; LOW DRUG DOSE; MALE; NERVOUSNESS; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOCIAL DEFICIT; SOCIAL RESPONSIVENESS SCALE; SOCIAL STATUS; TREATMENT RESPONSE; UNPLEASANT DREAM; COMPLICATION; LONGITUDINAL STUDY; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL COMMUNICATION DISORDER; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMETABOLITES; AUTISM SPECTRUM DISORDER; CYCLOSERINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SOCIAL COMMUNICATION DISORDER; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923377629     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.13070155     Document Type: Article

References (40)

1. Bellini S, Peters JK: Social skills training for youth with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17: 857–873, x
2. Wehman P, Smith M, Schall C: Autism and the Transition to Adulthood: Success Beyond the Classroom. Baltimore, Paul H. Brookes, 2009
3. Posey DJ, Erickson CA, McDougle CJ: Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17:787–801, viii–ix
4. Marino MJ, Conn PJ: Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 2006; 6:98–102
5. Won H, Lee HR, Gee HY, et al: Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012; 486:261–265
6. Halene TB, Ehrlichman RS, Liang Y, et al: Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009; 8:661–675
7. Labrie V, Lipina T, Roder JC: Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008; 200: 217–230
8. Burket JA, Herndon AL, Deutsch SI: Locomotor activity of the genetically inbred Balb/c mouse strain is suppressed by a socially salient stimulus. Brain Res Bull 2010; 83:255–256
9. Deutsch SI, Burket JA, Jacome LF, et al: D-Cycloserine improves the impaired sociability of the Balb/c mouse. Brain Res Bull 2011; 84:8–11
10. Posey DJ, Kem DL, Swiezy NB, et al: A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161: 2115–2117
11. Deutsch SI, Pepe GJ, Burket JA, et al: D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res 2012; 1439:96–107
12. Burket JA, Benson AD, Tang AH, et al: D-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. Brain Res Bull 2013; 96:62–70
13. Goff DC: D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012; 38:936–941
14. Goff DC, Cather C, Gottlieb JD, et al: Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106:320–327
15. Heaton LJ, McNeil DW, Milgrom PM: Propranolol and D-cycloserine as adjunctive medications in reducing dental fear in sedation practice. SAAD Dig 2010; 26:27–35
16. Rothbaum BO: Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry 2008; 165:293–296
17. Quartermain D, Mower J, Rafferty MF, et al: Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994; 257:7–12
18. Wilhelm S, Buhlmann U, Tolin DF, et al: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165:335–341, quiz 409
19. Javitt DC: Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9:984–997
20. Wechsler D: WASI: Wechsler Abbreviated Scale of Intelligence Manual. San Antonio, TX, Psychological Corporation, 1999
21. Aman MG, Singh NN, Stewart AW, et al: The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89:485–491
22. Shea S, Turgay A, Carroll A, et al: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634–e641
23. Aman MG, De Smedt G, Derivan A, et al: Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–1346
24. Aman MG, Kasper W, Manos G, et al: Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 2010; 20:415–422
25. Constantino JN, Gruber CP: Social Responsiveness Scale (SRS). Los Angeles, Western Psychological Services, 2005
26. Murray MJ, Mayes SD, Smith LA: Brief report: excellent agreement between two brief autism scales (Checklist for Autism Spectrum Disorder and Social Responsiveness Scale) completed independently by parents and the Autism Diagnostic Interview- Revised. J Autism Dev Disord 2011; 41:1586–1590
27. Hus V, Bishop S, Gotham K, et al: Factors influencing scores on the social responsiveness scale. J Child Psychol Psychiatry 2013; 54: 216–224
28. Wechsler D: Advanced Clinical Solutions for Use with WAIS-IV and WMS-IV. San Antonio, TX, Pearson, 2009
29. Crino PB: mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011; 17:734–742
30. Sahin M: Targeted treatment trials for tuberous sclerosis and autism: no longer a dream. Curr Opin Neurobiol 2012; 22:895–901
31. Ehninger D, Silva AJ: Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med 2011; 17:78–87
32. Talos DM, Sun H, Zhou X, et al: The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012; 7:e35885
33. Tsai PT, Hull C, Chu Y, et al: Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012; 488: 647–651
34. Cuscó I, Medrano A, Gener B, et al: Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet 2009; 18:1795–1804
35. Sharma A, Hoeffer CA, Takayasu Y, et al: Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30: 694–702
36. Paul S, Nairn AC, Wang P, et al: NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 2003; 6:34–42
37. Fitzpatrick CJ, Lombroso PJ: The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. Front Neuroanat 2011; 5:47
38. Paul S, Connor JA: NR2B-NMDA receptor-mediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling. J Neurochem 2010; 114:1107–1118
39. Zhou J, Blundell J, Ogawa S, et al: Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 2009; 29:1773–1783
40. Goff DC, Tsai G, Manoach DS, Coyle JT: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152:1213–1215